Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE). METHODS: An observational, nonrandomized, comparative multicenter cohort study was conducted at 17 Spanish and 1 Italian hospitals. Consecutive adult patients diagnosed of EFIE were included. Outcome measurements were death during treatment and at 3 months of follow-up, adverse events requiring treatment withdrawal, treatment failure requiring a change of antimicrobials, and relapse. RESULTS: A larger percentage of AC-treated patients (n = 159) had previous chronic renal failure than AG-treated patients (n = 87) (33% vs 16%, P = .004), and AC patients had a higher incidence of cancer (18% vs 7%, P = .015), transplantation (6% vs 0%, P = .040), and healthcare-acquired infection (59% vs 40%, P = .006). Between AC and AG-treated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P = .81) or at 3-month follow-up (8% vs 7%, P = .72), in treatment failure requiring a change in antimicrobials (1% vs 2%, P = .54), or in relapses (3% vs 4%, P = .67). However, interruption of antibiotic treatment due to adverse events was much more frequent in AG-treated patients than in those receiving AC (25% vs 1%, P < .001), mainly due to new renal failure (≥25% increase in baseline creatinine concentration; 23% vs 0%, P < .001). CONCLUSIONS: AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study by Fernández-Hidalgo et al, 191 26% of the 272 patients had high-level aminoglycoside-resistant strains of E faecalis.”
In the citing paper
“Sixth, in the larger study, there were no significant differences between ampicillin-ceftriaxone and ampicillin-gentamicin in the need for surgery, complications (except for fewer cases of renal failure in the ampicillin-ceftriaxone group), relapse, or mortality.”
In the citing paper
“Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the larger study.”
In the citing paper
“Fourth, in the larger study, the median age was 70 years in both treatment groups; however, patients in the ampicillin-ceftriaxone group were generally sicker and had more comorbid conditions (eg, chronic renal failure [P=0.004],neoplasm [P=0.015], and nosocomial acquisition of infection [P=0.006]).”
In the citing paper
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study 190 and 272 in the other study.191”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions IE was defined as definite or possible according to the modified Duke criteria [10].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey
Selton-Suty, C., Célard, M., Le Moing, V., Doco-Lecompte, T., Chirouze, C., Iung, B., Strady, C., Revest, M., Vandenesch, F., Bouvet, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis199 · Cited by 710
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525 · cited 1×
“Healthcare-associated IE [11] and catheter-related bacteremia [12] have been defined elsewhere.”
BackgroundContemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis
Fernández‐Hidalgo, N., Almirante, B., Tornos, P., Pigrau, C., Sambola, A., Igual, A., & Pahissa, A. (2008) · Clinical Infectious Diseases · doi:10.1086/592576 · Cited by 217
Self-citationGavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202 · cited 3×
“Since the publication of an observational, nonrandomized, multicenter clinical trial in 2007 [9], the ampicillin plus ceftriaxone (AC) combination has been recognized as a viable alternative for treating E.”
BackgroundSelf-citationMcDonald, J. R., Olaison, L., Anderson, D. J., Hoen, B., Miro, J. M., Eykyn, S., Abrutyn, E., Fowler, V. G., Habib, G., Selton-Suty, C., et al. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.020 · Cited by 170
Enterococcal Endocarditis in Sweden, 1995–1999: Can Shorter Therapy with Aminoglycosides Be Used?
Olaison, L., Schadewitz, K., & Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis (2002) · Clinical Infectious Diseases · doi:10.1086/338233 · Cited by 166
Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis
Mainardi, J. L., Gutmann, L., Acar, J. F., & Goldstein, F. W. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1984 · Cited by 164
Treatment of Streptomycin-Susceptible and Streptomycin-Resistant Enterococcal Endocarditis
WILSON, W. R., WILKOWSKE, C. J., WRIGHT, A. J., SANDE, M. A., & GERACI, J. E. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-6-816 · Cited by 159 · cited 1×
“The relapse rate for the overall series was similar to the reported rate of 7% of relapses in a retrospective Spanish study [5] of 47 episodes of EFIE, but far from the 0% reported by Wilson et al in 1984 [22].”
ResultGavaldà, J., Torres, C., Tenorio, C., López, P., Zaragoza, M., Capdevila, J. A., Almirante, B., Ruiz, F., Borrell, N., Gomis, X., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.639 · Cited by 134
Self-citationFernández‐Hidalgo, N., Almirante, B., Tornos, P., González-Alujas, M. T., Planes, A. M., Galiñanes, M., & Pahissa, A. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12033 · Cited by 120 · cited 2×
“Although the information about relapses in recent studies is scarce, a recent report described 2% of relapses in a general contemporary series of left-sided infective endocarditis [1].”
BackgroundSelf-citationFernández Guerrero, M. L., Goyenechea, A., Verdejo, C., Roblas, R. F., & de Górgolas, M. (2007) · Medicine · doi:10.1097/md.0b013e31815d5386 · Cited by 113
Gavalda, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg360 · Cited by 83
Self-citationFernández‐Guerrero, M. L., Herrero, L., Bellver, M., Gadea, I., Roblas, R. F., & De Górgolas, M. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01061.x · Cited by 80 · cited 1×
“The nosocomial origin of a considerable percentage of enterococcal bacteremia and endocarditis cases has been pointed out by Fernández-Guerrero et al [5, 16].”
BackgroundLa endocarditis infecciosa en el siglo xxi: cambios epidemiológicos, terapéuticos y pronósticos
Fernández‐Hidalgo, N., & Almirante, B. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.11.005 · Cited by 50
Self-citationEndocarditis por enterococo: análisis multicéntrico de 76 casos
Martínez‐Marcos, F. J., Lomas-Cabezas, J. M., Hidalgo-Tenorio, C., Lima, J. D. L. T., Plata, A., Reguera-Iglesias, J. M., Ruiz‐Morales, J., Márquez, M., Gálvez-Acebal, J., & de Alarcón-González, A. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.02.007 · Cited by 34
Self-citationFarina, C., Russello, G., Chinello, P., Pasticci, M. B., Raglio, A., Ravasio, V., Rizzi, M., Scarparo, C., Vailati, F., Suter, F., et al. (2011) · Chemotherapy · doi:10.1159/000330458 · Cited by 30
Dubé, L., Caillon, J., Jacqueline, C., Bugnon, D., Potel, G., & Asseray, N. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1594-x · Cited by 16 · cited 1×
“In one recently published study, gentamicin proved to be the most effective aminoglycoside for treating EFIE in a rabbit model, with best efficacy at 6 mg/kg/day [21].”
Background
Cited by
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study(190) and 272 in the other study.(191) Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the la…”
BackgroundResult2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Self-citationMechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772
“Seemingly redundant therapy, such as the combination of the b-lactams, ampicillin and ceftriaxone, has been shown clinically to be as efficacious as more traditional combinations with aminoglycosides, with the benefit of less toxicity and the ability to bypass high-level resistance to aminoglycosides [133,134].”
BackgroundThe Enterococcus: a Model of Adaptability to Its Environment
García-Solache, M., & Rice, L. B. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-18 · Cited by 754
“faecalis, and ceftriaxone, which is not (147, 148).”
Background
Metadata
- Authors
- Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., Gurgui, M., Peña, C., de Alarcón, A., Ruiz, J., Vilacosta, I., Montejo, M., Vallejo, N., López-Medrano, F., Plata, A., López, J., Hidalgo-Tenorio, C., Gálvez, J., Sáez, C., Lomas, J. M., Falcone, M., de la Torre, J., Martínez-Lacasa, X., & Pahissa, A.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Clínico San Carlos (ES)
- Hospital de Cruces (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Juan Ramón Jiménez (ES)
- Policlinico Umberto I (IT)
- University Hospital Mútua de Terrassa (ES)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 56
- Issue
- 9
- Pages
- 1261-1268
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137285136
- Semantic Scholar
- 9646599067b0e52124c95b08e69a38b3bd9e8a91
- Cited by
- 311
- References
- 22
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 16 · 2021: 19 · 2020: 26 · 2019: 35 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 16 · 2013: 19
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- Enterococcus faecalis, infective endocarditis, ampicillin, ceftriaxone, gentamicin, combination antibiotic therapy, aminoglycoside resistance, renal failure, treatment failure, relapse, mortality, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Ampicillin, Anti-Bacterial Agents, Ceftriaxone, Drug Therapy, Combination, Endocarditis, Female, Gentamicins, Hospitals, Humans, Italy, Male, Middle Aged, Spain, Enterococcus faecalis, Cohort Studies, Treatment Outcome, Gram-Positive Bacterial Infections, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.